TAICEND’s Patented Fish Collagen Technology Brings a Breakthrough in the Healing of Hard-to-Heal Wounds
Summary: TAICEND Technology unveiled its patented fish collagen series at Medica 2025, leveraging molecular medicine to accelerate hard-to-heal wound recovery by over 50%. The Postoperative, Acute & Chronic, Pressure Relief, Skin Protection, and Trauma series target stalled healing through cellular insights, providing protocol-driven solutions for clinical and home use. Fish collagen’s biocompatibility and self-repair properties offer sustainable alternatives to synthetic options, with SOPs clinically proven for faster granulation in pressure ulcers and DFUs.
Key Highlights:
- Series: Postoperative for infection/scar reduction; Chronic for pressure ulcers (50%+ healing speed).
- Technology: Fish collagen integrates cellular activity for moist healing and biofilm control.
- Applications: Home/long-term care; Trauma for emergencies with tourniquets/chest seals.
- Event: Medica 2025 booth; CEO: “From stalled to accelerated recovery.”
- Impact: Sustainable, protocol-driven; fosters global collaboration.
Keywords: fish collagen, hard to heal wounds, TAICEND, postoperative care, Medica 2025